Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03225196 · ClinicalTrials.gov registry record
Extracellular RNAs in Relation to Cardiometabolic Risk
A clinical trial of Obesity and Blood Pressure, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 4,495
- Enrollment target
- 1
- Study location
NCT03225196 is a study of Obesity and Blood Pressure that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 4,495 participants, above the 815-participant average among 1,053 other Obesity trials with a reported enrollment target (452% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03225196, a study of Obesity and Blood Pressure, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 4,495 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Extracellular RNAs (exRNAs) send genetic data from cell to cell. This is how they affect the way cells communicate with each other. There are many types of exRNA, and they each serve different roles. But they have also been linked to some diseases. Researchers want to measure exRNAs to see how they relate to certain traits over time. They will use blood samples that were taken as part of the Framingham Heart Study (FHS). Objectives: To identify cross-sectional associations of exRNAs with age, sex, and cardiometabolic risk factors. Eligibility: People ages 30-70 who had blood taken as part of the FHS Third Generation cohort. Design: Researchers will study samples that have already been collected in the FHS. There will be no active participant contact for this project, only use of data that are collected as part of planned follow up from other studies. As part of the FHS, participants gave blood samples. They gave permission for the blood to be used for research. The exRNAs from the blood samples will be studied to see how they relate to certain traits. These include age, sex, and body mass index. The exRNAs will also be studied for their usefulness as biomarkers of risk for subclinical atherosclerotic cardiovascular disease. No study participants will be contacted for this study....
Conditions Studied
Study Locations (1)
Massachusetts
- Framingham Heart Study - Framingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,495 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2020-06-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03225196
The ClinicalTrials.gov registry entry for NCT03225196 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,495 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 815-participant average among 1,053 other Obesity trials with a reported enrollment target (452% higher). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 0 interventions.
NCT03225196 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03225196 about?
NCT03225196 is a clinical study titled "Extracellular RNAs in Relation to Cardiometabolic Risk". Background: Extracellular RNAs (exRNAs) send genetic data from cell to cell. This is how they affect the way cells communicate with each other. There are many types of exRNA, and they each serve different roles. But they have also been linked to some diseases. Researchers want to measure exRNAs to ...
What is the current status of trial NCT03225196?
This trial is currently completed. The enrollment target is 4,495 participants. The study started on 2017-07-17. Estimated completion is 2020-06-11.
What conditions does trial NCT03225196 study?
This clinical trial studies the following conditions: Obesity, Blood Pressure, Subclinical Atherosclerotic Cardiovascular Disease.
Who is sponsoring clinical trial NCT03225196?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03225196 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.